Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023

Table of Contents

1 INTRODUCTION 18

1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKET COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22

2.1 RESEARCH DESIGN 22
2.1.1 SECONDARY DATA 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY DATA 23
2.1.2.1 Key data from primary sources 24
2.1.2.2 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 26
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 29
2.4 MARKET SHARE ESTIMATION 30
2.5 ASSUMPTIONS FOR THE STUDY 30

3 EXECUTIVE SUMMARY 31
4 PREMIUM INSIGHTS 35

4.1 OVERVIEW OF THE VACCINES MARKET 35
4.2 VACCINES MARKET, BY TYPE, 2018–2023 36
4.3 VACCINES MARKET, BY END USER, 2018 VS. 2023 (USD BILLION) 36
4.4 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY 37
4.5 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2018 VS. 2023 (USD BILLION) 38
4.6 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 38
 

5 MARKET OVERVIEW 39

5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 DRIVERS 40
5.2.1.1 High prevalence of infectious diseases 40
5.2.1.2 Rising focus on immunization programs 40
5.2.1.3 Growing government support for vaccine development 41
5.2.1.4 Increasing company initiatives to enhance vaccine R&D 42
5.2.2 RESTRAINTS 42
5.2.2.1 High cost of vaccine development 42
5.2.3 OPPORTUNITIES 42
5.2.3.1 High growth prospects in emerging markets 42
5.2.3.2 Focus on therapeutic vaccines 43
5.2.3.3 Use of adjuvants in vaccines 43
5.2.4 CHALLENGES 44
5.2.4.1 Inadequate access to vaccines 44
5.2.4.2 Product recalls 45

6 INDUSTRY INSIGHTS 46

6.1 REGULATORY LANDSCAPE 46
6.1.1 NORTH AMERICA 47
6.1.2 EUROPE 47
6.1.3 ASIA 48
6.1.4 ROW 48
6.2 KEY PIPELINE PRODUCTS 49
6.3 NEW VACCINE OPPORTUNITIES 50
6.3.1 HIV 50
6.3.1.1 HIV vaccine: product pipeline 50
6.3.1.2 HIV vaccine: public-private initiatives 51
6.3.1.3 HIV vaccine: funding 51
6.3.2 MALARIA 53
6.3.2.1 Malaria vaccine: product pipeline 53
6.3.2.2 Malaria vaccine: public-private initiatives 54
6.3.3 ZIKA 54
6.3.3.1 Zika vaccine: product pipeline 54
6.3.3.2 Zika vaccine: public-private initiatives 55
6.3.3.3 Zika vaccine: funding 55
6.3.4 EBOLA 55
6.3.4.1 Ebola vaccine: product pipeline 55
6.3.4.2 Ebola vaccine: public-private initiatives 56
6.3.4.3 Ebola vaccine: funding 56

7 VACCINES MARKET, BY TECHNOLOGY 57

7.1 INTRODUCTION 58
7.2 CONJUGATE VACCINES 59
7.3 INACTIVATED AND SUBUNIT VACCINES 60
7.4 LIVE ATTENUATED VACCINES 61
7.5 RECOMBINANT VACCINES 62
7.6 TOXOID VACCINES 63

8 VACCINES MARKET, BY TYPE 65

8.1 INTRODUCTION 66
8.2 MONOVALENT VACCINES 67
8.3 MULTIVALENT VACCINES 68

9 VACCINES MARKET, BY DISEASE INDICATION 70

9.1 INTRODUCTION 71
9.2 PNEUMOCOCCAL DISEASE 73
9.3 DTP 74
9.4 INFLUENZA 75
9.5 HPV 76
9.6 MENINGOCOCCAL DISEASE 77
9.7 POLIO 79
9.8 ROTAVIRUS 80
9.9 HEPATITIS 81
9.10 MMR 82
9.11 VARICELLA 83
9.12 DENGUE 84
9.13 HERPES ZOSTER 85
9.14 OTHER DISEASE INDICATIONS 85

10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 87

10.1 INTRODUCTION 88
10.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 89
10.3 ORAL ADMINISTRATION 90
10.4 OTHER ROUTES OF ADMINISTRATION 90

11 VACCINES MARKET, BY PATIENT TYPE 92

11.1 INTRODUCTION 93
11.2 PEDIATRIC PATIENTS 94
11.3 ADULT PATIENTS 95
 

12 VACCINES MARKET, BY REGION 97

12.1 INTRODUCTION 98
12.2 NORTH AMERICA 98
12.2.1 US 102
12.2.2 CANADA 103
12.3 EUROPE 104
12.3.1 GERMANY 108
12.3.2 UK 109
12.3.3 FRANCE 110
12.3.4 ITALY 111
12.3.5 SPAIN 112
12.3.6 ROE 112
12.4 ASIA 114
12.4.1 JAPAN 118
12.4.2 CHINA 119
12.4.3 INDIA 120
12.4.4 REST OF ASIA (ROA) 121
12.5 REST OF THE WORLD (ROW) 122

13 COMPETITIVE LANDSCAPE 127

13.1 OVERVIEW 127
13.2 MARKET SHARE ANALYSIS 128
13.3 COMPETITIVE SITUATION AND TRENDS 130
13.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 130
13.3.2 PRODUCT LAUNCHES AND APPROVALS 131
13.3.3 ACQUISITIONS 131
13.3.4 EXPANSIONS 132
 

14 COMPANY PROFILES 133

(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 PFIZER 133
14.2 GLAXOSMITHKLINE 137
14.3 MERCK 141
14.4 SANOFI PASTEUR 144
14.5 CSL LIMITED 148
14.6 EMERGENT BIOSOLUTIONS 151
14.7 JOHNSON & JOHNSON 154
14.8 MEDIMMUNE, LLC (A SUBSIDIARY OF ASTRAZENECA) 157
14.9 ASTELLAS PHARMA 159
14.10 SERUM INSTITUTE OF INDIA 161
14.11 BAVARIAN NORDIC 164
14.12 MITSUBISHI TANABE PHARMA CORPORATION 167
14.13 DAIICHI SANKYO COMPANY 170
14.14 PANACEA BIOTEC 173
14.15 BIOLOGICAL E 176
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
15 APPENDIX 178

LIST OF TABLES

TABLE 1 INCIDENCE OF DISEASES 40
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2013–2018 (USD MILLION) 41
TABLE 3 IMMUNIZATION COVERAGE, BY DISEASE, 2015 VS 2016 44
TABLE 4 REGULATORY AUTHORITIES IN EUROPE 47
TABLE 5 REGULATORY AUTHORITIES IN ASIA 48
TABLE 6 KEY PIPELINE VACCINES 49
TABLE 7 ESTIMATED INVESTMENTS IN HIV VACCINES, BY INVESTOR (2015–2016) 52
TABLE 8 EBOLA PROJECTS FUNDED BY EC (2014–2020) 56
TABLE 9 VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 58
TABLE 10 COST OF MENINGOCOCCAL CONJUGATE VACCINES 59
TABLE 11 CONJUGATE VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 60
TABLE 12 EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES 61
TABLE 13 INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION,
2016–2023 (USD MILLION) 61
TABLE 14 LIVE ATTENUATED VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 62
TABLE 15 EXAMPLES OF RECOMBINANT VACCINES 63
TABLE 16 RECOMBINANT VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 63
TABLE 17 TOXOID VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 64
TABLE 18 VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 66
TABLE 19 MONOVALENT VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 67
TABLE 20 EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET 68
TABLE 21 MULTIVALENT VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 69
TABLE 22 VACCINES MARKET, BY DISEASE INDICATION, 2016–2023 (USD MILLION) 72
TABLE 23 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET 73
TABLE 24 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION,
2016–2023 (USD MILLION) 74
TABLE 25 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET 74
TABLE 26 VACCINES MARKET FOR DTP, BY REGION, 2016–2023 (USD MILLION) 75
TABLE 27 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET 76
TABLE 28 VACCINES MARKET FOR INFLUENZA, BY REGION, 2016–2023 (USD MILLION) 76
TABLE 29 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 77
TABLE 30 VACCINES MARKET FOR HPV, BY REGION, 2016–2023 (USD MILLION) 77
TABLE 31 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 78
TABLE 32 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION,
2016–2023 (USD MILLION) 78
TABLE 33 LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET 79
TABLE 34 VACCINES MARKET FOR POLIO, BY REGION, 2016–2023 (USD MILLION) 80
TABLE 35 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET 80
TABLE 36 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2016–2023 (USD MILLION) 80
TABLE 37 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET 81
TABLE 38 VACCINES MARKET FOR HEPATITIS, BY REGION, 2016–2023 (USD MILLION) 81
TABLE 39 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET 82
TABLE 40 VACCINES MARKET FOR MMR, BY REGION, 2016–2023 (USD MILLION) 82
TABLE 41 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET 83
TABLE 42 VACCINES MARKET FOR VARICELLA, BY REGION, 2016–2023 (USD MILLION) 83
TABLE 43 VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2016–2023 (USD MILLION) 85
TABLE 44 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS IN THE MARKET 86
TABLE 45 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2016–2023 (USD MILLION) 86
TABLE 46 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD MILLION) 88
TABLE 47 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2016–2023 (USD MILLION) 89
TABLE 48 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION,
2016–2023 (USD MILLION) 90
TABLE 49 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION,
2016–2023 (USD MILLION) 91
TABLE 50 VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 93
TABLE 51 VACCINES MARKET FOR PEDIATRIC PATIENTS, BY REGION,
2016–2023 (USD MILLION) 94
TABLE 52 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2016–2023 (USD MILLION) 95
TABLE 53 VACCINES MARKET FOR ADULT PATIENTS, BY REGION, 2016–2023 (USD MILLION) 96
TABLE 54 NORTH AMERICA: VACCINES MARKET FOR ADULT PATIENTS, BY COUNTRY,
2016–2023 (USD MILLION) 96
TABLE 55 VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 98
TABLE 56 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 100
TABLE 57 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY,
2016–2023 (USD MILLION) 100
TABLE 58 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 100
TABLE 59 NORTH AMERICA: VACCINES MARKET, 2016–2023 (USD MILLION) 101
TABLE 60 NORTH AMERICA: VACCINES MARKET, 2016–2023 (USD MILLION) 101
TABLE 61 NORTH AMERICA: VACCINES MARKET, BY PATIENT TYPE,
2016–2023 (USD MILLION) 102
TABLE 62 US: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 103
TABLE 63 US: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 103
TABLE 64 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 104
TABLE 65 CANADA: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 104
TABLE 66 EUROPE: VACCINES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 106
TABLE 67 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 106
TABLE 68 EUROPE: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 106
TABLE 69 EUROPE: VACCINES MARKET, BY DISEASE INDICATION,
2016–2023 (USD MILLION) 107
TABLE 70 EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2016–2023 (USD MILLION) 108
TABLE 71 EUROPE: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 108
TABLE 72 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 109
TABLE 73 UK: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 110
TABLE 74 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 111
TABLE 75 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 111
TABLE 76 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 112
TABLE 77 ROE: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 113
TABLE 78 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000, 2014 & 2016 (USD) 114
TABLE 79 ASIA: VACCINES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 116
TABLE 80 ASIA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 116
TABLE 81 ASIA: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 116
TABLE 82 ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2016–2023 (USD MILLION) 117
TABLE 83 ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2016–2023 (USD MILLION) 117
TABLE 84 ASIA: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 118
TABLE 85 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 118
TABLE 86 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 119
TABLE 87 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 120
TABLE 88 ROA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 121
TABLE 89 ROW: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 124
TABLE 90 ROW: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 124
TABLE 91 ROW: VACCINES MARKET, 2016–2023 (USD MILLION) 125
TABLE 92 ROW: VACCINES MARKET, 2016–2023 (USD MILLION) 125
TABLE 93 ROW: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 126

LIST OF FIGURES

FIGURE 1 VACCINES MARKET SEGMENTATION 19
FIGURE 2 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 26
FIGURE 3 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 27
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 28
FIGURE 5 DATA TRIANGULATION METHODOLOGY 29
FIGURE 6 VACCINES MARKET, BY TECHNOLOGY, 2018–2023 31
FIGURE 7 VACCINES MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION) 32
FIGURE 8 VACCINES MARKET, BY DISEASE INDICATION, 2018 VS. 2023 (USD BILLION) 32
FIGURE 9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2018 VS. 2023 (USD BILLION) 33
FIGURE 10 VACCINES MARKET, BY PATIENT TYPE, 2018 VS. 2023 (USD BILLION) 33
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 34
FIGURE 12 HIGH PREVALENCE OF DISEASES AND RISING FOCUS ON IMMUNIZATION PROGRAMS ARE DRIVING MARKET GROWTH 35
FIGURE 13 MONOVALENT VACCINES SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 36
FIGURE 14 PEDIATRICS SEGMENT TO DOMINATE THE VACCINES MARKET IN
2023 (USD BILLION) 36
FIGURE 15 CONJUGATE VACCINES SEGMENT TO HOLD LARGEST SHARE OF THE VACCINES MARKET IN 2018 37
FIGURE 16 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 38
FIGURE 17 US TO DOMINATE THE VACCINES MARKET IN 2018 38
FIGURE 18 VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
FIGURE 19 REGULATORY APPROVAL PROCESS FOR VACCINES 46
FIGURE 20 R&D FUNDING FOR HIV PREVENTIVE VACCINES, BY INVESTOR, 2016 52
FIGURE 21 CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINES MARKET DURING THE FORECAST PERIOD 58
FIGURE 22 MONOVALENT VACCINES TO GROW AT THE HIGHEST RATE IN THE VACCINES MARKET, BY TYPE 66
FIGURE 23 PNEUMOCOCCAL DISEASE SEGMENT TO LEAD VACCINES MARKET, BY DISEASE INDICATION, DURING 2018–2023 71
FIGURE 24 VACCINES MARKET FOR DENGUE, 2016–2023 (USD MILLION) 84
FIGURE 25 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO ACCOUNT FOR THE VACCINES MARKET, 2018–2023 (USD MILLION) 88
FIGURE 26 PEDIATRIC PATIENTS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE VACCINES MARKET, 2018 (USD MILLION) 93
FIGURE 27 NORTH AMERICA: VACCINES MARKET SNAPSHOT 99
FIGURE 28 EUROPE: VACCINES MARKET SNAPSHOT 105
FIGURE 29 ASIA: VACCINES MARKET SNAPSHOT 115
FIGURE 30 ROW: VACCINES MARKET SNAPSHOT 123
FIGURE 31 KEY DEVELOPMENTS IN THE VACCINE MARKET FROM 2015 TO 2018 127
FIGURE 32 MARKET EVOLUTION FRAMEWORK 128
FIGURE 33 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 129
FIGURE 34 PFIZER: COMPANY SNAPSHOT (2017) 133
FIGURE 35 GLAXOSMITHKLINE: COMPANY SNAPSHOT (2017) 137
FIGURE 36 MERCK: COMPANY SNAPSHOT (2017) 141
FIGURE 37 SANOFI PASTEUR: COMPANY SNAPSHOT (2017) 144
FIGURE 38 CSL LIMITED: COMPANY SNAPSHOT (2017) 148
FIGURE 39 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT (2017) 151
FIGURE 40 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017) 154
FIGURE 41 ASTRAZENECA: COMPANY SNAPSHOT (2017) 157
FIGURE 42 ASTELLAS PHARMA: COMPANY SNAPSHOT (2017) 159
FIGURE 43 BAVARIAN NORDIC: COMPANY SNAPSHOT (2017) 164
FIGURE 44 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT (2017) 167
FIGURE 45 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2017) 170
FIGURE 46 PANACEA BIOTEC: COMPANY SNAPSHOT (2017) 173

当レポートのプレスリリースは発行されておりません。